Next-Generation FeNO Testing Devices Market

The Next-Generation FeNO Testing Devices Market is analyzed across its key device configuration, clinical care location, consumable model and patient use profile segments, with the study covering market dynamics, regional trends and demand outlook, forecast 2026 to 2036.

By Fact.MR Industrial Goods Desk Lead analyst: Shubham Patidar Updated : 11 min read Fact-checked under the Fact.MR editorial process

  • Market Value (2025): USD 27.0 Mn
  • Estimated Value (2026): USD 30.5 Mn
  • Forecast Value (2036): USD 101.5 Mn
  • CAGR (2026-2036): 12.8%

Next-Generation FeNO Testing Devices Market Forecast and Outlook 2026 to 2036

The next-generation FeNO testing devices market is projected to grow from USD 30.5 million in 2026 to USD 101.5 million by 2036. Demand for next-generation FeNO testing devices is likely to grow at a CAGR of 12.8% over the forecast period.

Demand for next-generation FeNO testing devices is rising as asthma guidelines move fractional exhaled nitric oxide from specialist laboratories into routine diagnosis and monitoring. Suppliers of FeNO devices are developing connected, cartridge-based and home-use analyzers that send results to records and care teams. For example, in March 2026, NIOX Group reported that the number of NIOX FeNO tests sold in 2025 rose 9% to 7.2 million, which it described as evidence of strong adoption and recurring use. Similar growth in test volumes is projected to drive sales of next-generation FeNO testing devices across primary and specialist care.

Key Takeaways from the Next-Generation FeNO Testing Devices Market

  • Sales of next-generation FeNO testing devices stood at USD 27.0 million in 2025
  • Next-Generation FeNO Testing Devices Market Value (2026): USD 30.5 million
  • Next-Generation FeNO Testing Devices Market Forecast Value (2036): USD 101.5 million
  • Next-Generation FeNO Testing Devices Market Forecast CAGR (2026-2036): 12.8%
  • Leading Device Configuration: Remote-connected analyzer (23.0%)
  • Key Market Participants: NIOX Group, Bedfont Scientific, Bosch Healthcare Solutions, Eco Medics, Sunvou Medical Electronics, Vyaire Medical
  • Key Growth Regions: United States, China, Germany, United Kingdom, Japan

In October 2026, Bedfont Scientific and its U.S. partner coVita highlighted breath analysis technology ahead of CHEST 2026 as Bedfont sought to further penetrate the U.S. market with its NObreath FeNO device. Demand for next-generation FeNO testing devices is growing as manufacturers widen distribution beyond their home markets. Suppliers of FeNO devices are pairing device placements with consumables and data services. Similar market-entry efforts are projected to drive sales of next-generation FeNO testing devices across North America, Europe and Asia.

Next-Generation FeNO Testing Devices Market

Metric Value
Estimated Value in (2026) USD 30.5 million
Forecast Value in (2036) USD 101.5 million
Forecast CAGR (2026 to 2036) 12.8%

Source: Fact.MR analysis. Updated Nov 20, 2026

Source: Fact.MR analysis. Updated 17 Nov 2026

Next Generation Feno Testing Devices Forecast Global

Next Generation Feno Testing Devices Forecast Global | Source: Fact.MR

Category

Category Segments
Device Configuration Remote-connected analyzer, Handheld analyzer, Portable cartridge system, Integrated clinical workstation, Benchtop analyzer
Clinical Care Location Pediatric care, Pulmonology clinic, Allergy / immunology, Primary care, Home / remote
Consumable Model Service subscription, Disposable cartridge, Single-use mouthpiece, Calibration gas / kit, Reusable sensor
Patient Use Profile COPD, Pediatric asthma, Adult asthma, Diagnostic evaluation, Longitudinal monitoring
Region United States; China; Germany; United Kingdom; Japan

Source: Fact.MR analysis. Updated Nov 20, 2026

Source: Fact.MR analysis. Updated 17 Nov 2026

Segmental Analysis

Why do remote-connected analyzers lead device configuration in the Next-Generation FeNO Testing Devices Market?

Next Generation Feno Testing Devices Breakdown Feno Device Configuration

Next Generation Feno Testing Devices Breakdown Feno Device Configuration | Source: Fact.MR

Remote-connected analyzers account for 23.0% of the next-generation FeNO testing devices market in 2026, about USD 7.0 million, as clinics want FeNO results to flow automatically into electronic records and asthma registers. Connectivity also lets manufacturers monitor device use and consumable needs. Suppliers of FeNO devices are adding cloud links and remote quality checks, a direction tracked in Fact.MR's cloud-connected FeNO systems market study. Similar digital-integration needs are projected to keep remote-connected analyzers the leading configuration.

How is pediatric care leading clinical demand in the Next-Generation FeNO Testing Devices Market?

Next Generation Feno Testing Devices Breakdown Clinical Care Location

Next Generation Feno Testing Devices Breakdown Clinical Care Location | Source: Fact.MR

Pediatric care accounts for 29.7% of next-generation FeNO testing devices revenue in 2026, about USD 9.1 million, because FeNO needs only a steady exhalation and is easier for children than many lung-function tests. Pediatric clinicians use FeNO to support diagnosis and to check adherence to inhaled corticosteroids. Suppliers of FeNO devices are offering child-friendly flow guidance and shorter exhalation modes. Similar clinical suitability is projected to keep pediatric care the leading care location for next-generation FeNO testing devices.

Why do service subscriptions lead consumable models in the Next-Generation FeNO Testing Devices Market?

Next Generation Feno Testing Devices Breakdown Device Consumable Model

Next Generation Feno Testing Devices Breakdown Device Consumable Model | Source: Fact.MR

Service subscriptions account for 30.5% of next-generation FeNO testing devices revenue in 2026, about USD 9.3 million, as clinics prefer predictable monthly fees covering sensors, software, calibration and support over large upfront purchases. Subscriptions also lower the barrier for primary-care practices adopting FeNO for the first time. Suppliers of FeNO devices are bundling hardware, tests and connectivity into managed services. Similar procurement preferences are projected to keep service subscriptions the leading consumable model, supporting connected asthma management FeNO devices.

How is COPD shaping patient demand in the Next-Generation FeNO Testing Devices Market?

Next Generation Feno Testing Devices Breakdown Patient Use Profile

Next Generation Feno Testing Devices Breakdown Patient Use Profile | Source: Fact.MR

COPD accounts for 27.4% of next-generation FeNO testing devices revenue in 2026, about USD 8.4 million, as clinicians look for markers of type 2 inflammation that help identify COPD patients likely to respond to inhaled steroids or biologics. NIOX positions its NIOX VERO device for both asthma and COPD management. Suppliers of FeNO devices are generating evidence for COPD phenotyping alongside asthma. Similar interest in targeted COPD therapy is projected to drive sales of next-generation FeNO testing devices in this patient group.

Next-Generation FeNO Testing Devices Market-Drivers, Restraints & Trends

Drivers:

Demand for next-generation FeNO testing devices is rising as guidelines recommend objective tests for asthma diagnosis and monitoring. For example, the 2024 BTS/SIGN/NICE asthma guideline recommends using FeNO to help monitor treatment at routine asthma reviews, and a randomized trial of FeNO-guided management in primary care was presented in November 2026. Suppliers of FeNO devices are supporting practices that need to meet these recommendations. Similar guideline adoption is projected to drive sales of next-generation FeNO testing devices through the forecast period.

Restraints:

Demand for next-generation FeNO testing devices is limited by the cost of devices and consumables and by uneven funding for primary-care diagnostics. For example, in January 2026, a Lewisham health board paper noted that committed funding was required to purchase FeNO machines for primary care. Similar budget constraints are projected to slow sales of next-generation FeNO testing devices in publicly funded systems. Suppliers of FeNO devices must offer leasing, subscription and shared-service models to reduce upfront costs.

Trend: Home FeNO Monitoring

Demand for FeNO devices designed for patient use at home is rising as clinicians seek to track airway inflammation between visits. Suppliers of FeNO devices are developing compact sensors that patients can operate without supervision. For example, Bosch Healthcare Solutions' Vivatmo me, a CE-marked FeNO device for regular home use, was evaluated in the FeNO@Home study published in late 2025. Similar remote-monitoring programs are projected to drive sales of next-generation FeNO testing devices that link with smart inhalers and digital asthma platforms.

Trend: Capital Discipline Among FeNO Specialists

In September 2026, NIOX Group reported first-half revenue of GBP 24.0 million and proposed a GBP 12.5 million tender offer to return excess capital to shareholders. Demand for FeNO testing remains steady in clinical settings even as research demand normalizes after an exceptional 2025. Similar financial focus is projected to shape how specialists invest in next-generation FeNO testing devices. Suppliers of FeNO devices are prioritizing recurring clinical consumables over volatile research sales.

Next-Generation FeNO Testing Devices Market by Analysis by Key Country

Next Generation Feno Testing Devices Growth Index

Next Generation Feno Testing Devices Growth Index | Source: Fact.MR

Country CAGR (2026-2036)
United States 15.1%
China 15.0%
Germany 14.9%
United Kingdom 14.4%
Japan 11.4%

Source: Fact.MR analysis. Updated Nov 20, 2026

Source: Fact.MR analysis. Updated 17 Nov 2026

What is driving next-generation FeNO testing devices demand in the United States?

In October 2026, Bedfont Scientific and coVita promoted the NObreath FeNO device ahead of CHEST 2026 as part of Bedfont's effort to expand in the U.S.

Next Generation Feno Testing Devices Forecast Usa

Next Generation Feno Testing Devices Forecast Usa | Source: Fact.MR

market. Demand for next-generation FeNO testing devices in the United States is projected to grow at a 15.1% CAGR, the fastest among the five key countries, as allergists and pulmonologists use FeNO to select patients for biologic therapies. Suppliers of FeNO devices are building U.S. distribution and reimbursement support. Similar competitive entry is projected to drive sales in the United States.

How is under-testing creating headroom for next-generation FeNO testing devices in China?

Sales of next-generation FeNO testing devices in China are projected to grow at a 15.0% CAGR as hospitals expand biomarker-guided asthma care.

For example, a Chinese retrospective study published in July 2026 found that FeNO was measured in only 8.1% of patients receiving medium-to-high dose inhaled therapy during follow-up. Suppliers of FeNO devices, including domestic makers such as Sunvou, are targeting this testing gap with lower-cost analyzers. Similar room for wider testing is projected to drive sales of next-generation FeNO testing devices in China.

What is shaping next-generation FeNO testing devices demand in Germany?

Demand for next-generation FeNO testing devices in Germany is projected to grow at a 14.9% CAGR as German developers bring home-use FeNO technology to market.

Bosch Healthcare Solutions, based in Germany, developed the Vivatmo system to measure FeNO for asthma management, including the Vivatmo me device for home use. Suppliers of FeNO devices are working with German pulmonologists and pharmacies on monitoring programs. Similar domestic innovation is projected to drive sales of next-generation FeNO testing devices in Germany.

Why are guidelines supporting next-generation FeNO testing devices sales in the United Kingdom?

Sales of next-generation FeNO testing devices in the United Kingdom are projected to grow at a 14.4% CAGR as primary care implements the 2024 BTS/SIGN/NICE asthma guideline.

In November 2026, the DEFINE trial of online FeNO-guided asthma management in primary care was presented at the British Thoracic Society winter meeting. Suppliers of FeNO devices are supporting GP practices and integrated care boards with devices and training. Similar guideline-led adoption is projected to drive sales of next-generation FeNO testing devices in the United Kingdom.

How is asthma control shaping next-generation FeNO testing devices demand in Japan?

Demand for next-generation FeNO testing devices in Japan is projected to grow at an 11.4% CAGR, the slowest among the five countries, as an established FeNO user base grows steadily.

In August 2026, AstraZeneca Japan cited Ministry of Health, Labour and Welfare data estimating about 1.85 million asthma patients in Japan, with nearly half of those on dual therapy described as uncontrolled. Suppliers of FeNO devices are positioning testing to guide treatment escalation. Similar control gaps are projected to support sales in Japan.

Competitive Landscape for Next-Generation FeNO Testing Devices Market

Competition in the next-generation FeNO testing devices market is concentrated among a few specialist breath-analysis companies. NIOX Group competes through its NIOX VERO point-of-care platform and large installed base, Bedfont Scientific through the NObreath device, Bosch Healthcare Solutions through the Vivatmo system, and Eco Medics, Sunvou Medical Electronics and Vyaire Medical through clinical and research analyzers. Buyers select suppliers on measurement accuracy, cost per test, connectivity, ease of use for children and service support.

From 2025 onward, competition shifted toward recurring consumables and geographic expansion. NIOX reported 7.2 million tests sold in 2025 and focused on clinical growth as research demand normalized, Bedfont pushed further into the U.S. market in October 2026, and Chinese manufacturers targeted low testing rates at home. Suppliers with connected devices and subscription models are best placed to win primary-care adoption.

Recent Developments

  • In October 2026, Bedfont Scientific and coVita highlighted the NObreath FeNO device ahead of CHEST 2026 to expand in the U.S. market.
  • In September 2026, NIOX Group reported first-half revenue of GBP 24.0 million and proposed a GBP 12.5 million tender offer.
  • In May 2026, Bedfont Scientific targeted international growth for NObreath at the EAACI Congress 2026.
  • In March 2026, NIOX Group reported that FeNO tests sold in 2025 rose 9% to 7.2 million.

Key Players in Next-Generation FeNO Testing Devices Market

Key companies operating in the market include NIOX Group, Bedfont Scientific, Bosch Healthcare Solutions, Eco Medics, Sunvou Medical Electronics, and Vyaire Medical.

  • NIOX Group
  • Bedfont Scientific
  • Bosch Healthcare Solutions
  • Eco Medics
  • Sunvou Medical Electronics
  • Vyaire Medical

Bibliography

Market Breakdown

Segmentation

Scope of Report

Next Generation Feno Testing Devices Taxonomy

Next Generation Feno Testing Devices Taxonomy | Source: Fact.MR

Items Values
Quantitative Units (2026) USD 30.5 Million
Device Configuration Remote-connected analyzer, Handheld analyzer, Portable cartridge system, Integrated clinical workstation, Benchtop analyzer
Clinical Care Location Pediatric care, Pulmonology clinic, Allergy / immunology, Primary care, Home / remote
Consumable Model Service subscription, Disposable cartridge, Single-use mouthpiece, Calibration gas / kit, Reusable sensor
Patient Use Profile COPD, Pediatric asthma, Adult asthma, Diagnostic evaluation, Longitudinal monitoring
Regions Covered North America, Latin America, Europe, East Asia, South Asia and Pacific, Middle East & Africa
Countries Covered United States, China, Germany, United Kingdom, Japan, and other countries
Key Companies Profiled NIOX Group, Bedfont Scientific, Bosch Healthcare Solutions, Eco Medics, Sunvou Medical Electronics, Vyaire Medical
Additional Attributes Dollar revenue in the Next-Generation FeNO Testing Devices Market is segmented by device configuration (remote-connected, handheld, portable cartridge, integrated clinical workstation, benchtop), clinical care location, consumable model, patient use profile and region.

Source: Fact.MR analysis. Updated Nov 20, 2026

Source: Fact.MR analysis. Updated 17 Nov 2026

Next-Generation FeNO Testing Devices Market by Segments

  • Device Configuration

    • Remote-connected analyzer
    • Handheld analyzer
    • Portable cartridge system
    • Integrated clinical workstation
    • Benchtop analyzer
  • Clinical Care Location

    • Pediatric care
    • Pulmonology clinic
    • Allergy / immunology
    • Primary care
    • Home / remote
  • Consumable Model

    • Service subscription
    • Disposable cartridge
    • Single-use mouthpiece
    • Calibration gas / kit
    • Reusable sensor
  • Patient Use Profile

    • COPD
    • Pediatric asthma
    • Adult asthma
    • Diagnostic evaluation
    • Longitudinal monitoring
  • Region:

    • North America
      • United States
      • Canada
      • Mexico
    • Europe
      • Germany
      • United Kingdom
      • France
      • Italy
      • Spain
      • Rest of Europe
    • Asia Pacific
      • China
      • India
      • Japan
      • South Korea
      • Australia
      • Rest of Asia Pacific
    • Latin America
      • Brazil
      • Mexico
      • Argentina
      • Rest of Latin America
    • Middle East & Africa
      • GCC Countries
      • South Africa
      • Rest of Middle East & Africa
Questions Answered

Frequently Asked Questions

How big is the global Next-Generation FeNO Testing Devices Market in 2026?
The global Next-Generation FeNO Testing Devices Market is valued at approximately USD 30.5 million in 2026.
What will be the size of the Next-Generation FeNO Testing Devices Market by 2036?
The market is projected to reach around USD 101.5 million by 2036.
How fast will the Next-Generation FeNO Testing Devices Market grow during the forecast period?
The market is expected to grow at a CAGR of 12.8% between 2026 and 2036.
Which device configuration segment holds the largest share of the Next-Generation FeNO Testing Devices Market?
Remote-connected analyzer holds the largest share, accounting for about 23.0% of total revenue.

Who worked on this report

Shubham Patidar

Author

Shubham Patidar

Principal Consultant

LinkedIn

Preview the report firsthand - request a free sample

Free Sample

Get the brochure for pricing and purchase details

Download PDF
Explore More

Related Reports

Next-Generation FeNO Testing Devices Market

Request a Free Sample

Your personal details are safe with us. Privacy Policy

Share this image

Copy the code below to embed this image, with attribution, on your site.